Cargando…

Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer

BACKGROUND: Homologous recombination deficiency (HRD) is a molecular biomarker for administrating PARP inhibitor (PARPi) or platinum-based (Pt) chemotherapy. The most well-studied mechanism of causing HRD is pathogenic BRCA1/2 mutations, while HRD phenotype is also present in patients without BRCA1/...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wen, Hao, Feng, Zheng, Ma, Yutong, Liu, Rui, Ou, Qiuxiang, Guo, Qinhao, Shen, Yi, Wu, Xue, Shao, Yang, Bao, Hua, Wu, Xiaohua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109318/ https://www.ncbi.nlm.nih.gov/pubmed/35578198 http://dx.doi.org/10.1186/s12885-022-09602-4

Ejemplares similares

Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma
por: Feng, Zheng, et al.
Publicado: (2023)

Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer
por: Chen, Yimeng, et al.
Publicado: (2023)

Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib
por: Botrus, Gehan, et al.
Publicado: (2022)

Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes
por: da Costa, Alexandre A. B. A., et al.
Publicado: (2019)

Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration
por: Tsang, Erica S., et al.
Publicado: (2023)

Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies
por: Pokataev, Ilya, et al.
Publicado: (2020)

Establish of an Initial Platinum-Resistance Predictor in High-Grade Serous Ovarian Cancer Patients Regardless of Homologous Recombination Deficiency Status
por: Li, Yongmei, et al.
Publicado: (2022)

Platinum-Based Neoadjuvant Chemotherapy Before Radical Prostatectomy for Locally Advanced Prostate Cancer With Homologous Recombination Deficiency: A Case Report
por: Zhuang, Junlong, et al.
Publicado: (2022)

Platinum-based chemotherapy for pancreatic cancer: impact of mutations in the homologous recombination repair and Fanconi anemia genes
por: Emelyanova, Marina, et al.
Publicado: (2022)

RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer
por: Walens, Andrea, et al.
Publicado: (2022)

Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management
por: da Cunha Colombo Bonadio, Renata Rodrigues, et al.
Publicado: (2018)

Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer
por: Bouberhan, Sara, et al.
Publicado: (2020)

Biomarkers for Homologous Recombination Deficiency in Cancer
por: Wagener-Ryczek, Svenja, et al.
Publicado: (2021)

Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status Phase II LIGHT study primary analysis
por: Cadoo, Karen, et al.
Publicado: (2022)

Weekly platinum chemotherapy for recurrent ovarian cancer
por: Clamp, A, et al.
Publicado: (2002)

Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers
por: Watkins, Johnathan A, et al.
Publicado: (2014)

Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction
por: Chiang, Ying-Cheng, et al.
Publicado: (2021)

Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic Approaches
por: Mangogna, Alessandro, et al.
Publicado: (2023)

Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers
por: ter Brugge, Petra, et al.
Publicado: (2023)

Pan-cancer landscape of homologous recombination deficiency
por: Nguyen, Luan, et al.
Publicado: (2020)

Determinants of Homologous Recombination Deficiency in Pancreatic Cancer
por: Wattenberg, Max M., et al.
Publicado: (2021)

RNA-binding proteins in ovarian cancer: a novel avenue of their roles in diagnosis and treatment
por: Wu, Jiangchun, et al.
Publicado: (2022)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer
por: Della Pepa, Chiara, et al.
Publicado: (2014)

Ovarian cancer resistance to PARPi and platinum-containing chemotherapy
por: Summey, Rebekah, et al.
Publicado: (2022)

Homologous recombination deficiency predicts the response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: a systematic review and meta-analysis
por: Zhang, Liulu, et al.
Publicado: (2022)

Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy
por: Uno, Kaname, et al.
Publicado: (2022)

Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma
por: Christinat, Yann, et al.
Publicado: (2023)

Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer
por: Patel, Jai N., et al.
Publicado: (2018)

Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature
por: Frey, Melissa K., et al.
Publicado: (2017)

Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors
por: Miller, Rowan E, et al.
Publicado: (2022)

Homologous recombination proficiency in ovarian and breast cancer patients
por: Creeden, Justin Fortune, et al.
Publicado: (2021)

Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System
por: Wiedemeyer, W. Ruprecht, et al.
Publicado: (2014)

Dynamically Accumulating Homologous Recombination Deficiency Score Served as an Important Prognosis Factor in High-Grade Serous Ovarian Cancer
por: Su, Rongjia, et al.
Publicado: (2021)

ZNF76 predicts prognosis and response to platinum chemotherapy in human ovarian cancer
por: Hua, Tian, et al.
Publicado: (2021)

Next-generation sequencing of homologous recombination genes could predict efficacy of platinum-based chemotherapy in non-small cell lung cancer
por: Zhang, Linlin, et al.
Publicado: (2022)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer [Corrigendum]
Publicado: (2014)

Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer
por: Yang, Ling, et al.
Publicado: (2022)

Phase I trial of ribociclib with platinum chemotherapy in ovarian cancer
por: Coffman, Lan G., et al.
Publicado: (2022)

Heterogeneous effects of cytotoxic chemotherapies for platinum-resistant ovarian cancer
por: Nara, Katsuhiko, et al.
Publicado: (2023)

Homologous Recombination Pathway Alternation Predicts Prognosis of Colorectal Cancer With Chemotherapy
por: Lin, Yan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_70t166nm7qdi6ouhhg34senrnb